Pirtobrutinib shows evidence to inaugurate a third generation of BTK inhibitors

The Bruton's tyrosine kinase (BTK) protein is a crucial component of antigen-dependent B-cell receptor signalling that regulates B-cell development and maturation. BTK is also implicated in major processes of malignant B non-Hodgkin lymphoma (NHL-B) and chronic lymphocytic leukaemia (CLL) cells such as proliferation, survival, and trafficking. BTK inhibition has a profound effect on malignant cell survival. 1 Wen T Wang J Shi Y Qian H Liu P Inhibitors targeting Bruton's tyrosine kinase in cancers: drug development advances. Leukemia. 2020; (published online Oct 29.)https://doi.org/10.1038/s41375-020-01072-6 Google Scholar Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 studyPirtobrutinib was safe and active in multiple B-cell malignancies, including patients previously treated with covalent BTK inhibitors. Pirtobrutinib might address a growing unmet need for alternative therapies for these patients. Full-Text PDF